HCV Protease

HCV Protease Products

  • All (26)
  • HCV Protease Inhibitors (26)
  • New HCV Protease Products
Catalog No. Product Name Information Product Use Citations Product Validations
S1482 Daclatasvir (BMS-790052) Daclatasvir (BMS-790052, EBP883) is a highly selective inhibitor of HCV NS5A with EC50 of 9-50 pM, for a broad range of HCV replicon genotypes and the JFH-1 genotype 2a infectious virus in cell culture. Phase 3.
J Med Virol, 2024, 96(7):e29787
EMBO Mol Med, 2024, 16(4):870-884
J Virol, 2024, e0192123.
S1538 Telaprevir Telaprevir is an HCV NS3-4A serine protease inhibitor with IC50 of 0.35 μM.
J Virol, 2024, e0192123.
bioRxiv, 2023, 2023.11.22.568224
NPJ Digit Med, 2022, 5(1):83
S2794 Sofosbuvir Sofosbuvir is a HCV NS5B polymerase inhibitor for the treatment of chronic hepatitis C virus (HCV) infection.
J Med Virol, 2024, 96(7):e29787
PLoS One, 2024, 19(5):e0303265
mBio, 2023, 10.1128/mbio.01318-23
S1480 Lomibuvir (VX-222) Lomibuvir (VX-222, VCH-222) is a novel, potent and selective inhibitor of HCV polymerase with IC50 of 0.94-1.2 μM, 15.3-fold less effective for mutant M423T, and 108-fold less effective for mutant I482L. Phase 2.
Cell Death Discov, 2022, 8(1:446)
J Virol, 2022, jvi0190621
Sci Rep, 2021, 11(1):19443
S1183 Danoprevir Danoprevir is a peptidomimetic inhibitor of the NS3/4A protease of hepatitis C virus (HCV) with IC50 of 0.2-3.5 nM, inhibition effect for HCV genotypes 1A/1B/4/5/6 is ~10-fold higher than 2B/3A. Phase 2.
Antimicrob Agents Chemother, 2024, 68(4):e0137323.
Viruses, 2023, 15(4)981
Cell Rep Methods, 2023, 3(10):100599
S3733 Boceprevir Boceprevir (EBP 520, SCH 503034) is an oral, direct acting hepatitis C virus (HCV) protease inhibitor with Ki value of 14 nM for NS3. It is used in combination with other antiviral agents in the treatment of chronic hepatitis C, genotype 1.
Eur J Med Chem, 2024, 268:116202
Int J Mol Sci, 2024, 25(11)5767
SLAS Discov, 2024, S2472-5552(24)00043-1
S5062 Daclatasvir Dihydrochloride Daclatasvir is an orally available antiviral agent that inhibits the NS5A region of the hepatitis C virus (HCV) used for the treatment of chronic HCV genotype 1 and 3 infection.
Commun Biol, 2022, 5(1):154
J Antimicrob Chemother, 2021, 76(7):1874-1885
Med Mol Morphol, 2021, 10.1007/s00795-020-00271-5
S7579 Ledipasvir (GS5885) Ledipasvir (GS5885) is a HCV NS5A polymerase inhibitor, used for the treatment of hepatitis C virus infection.
Sci Rep, 2021, 11(1):19443
Cancers (Basel), 2019, 11(10)E1407
Biol Pharm Bull, 2019, 10.1248/bpb.b19-00641
S5015 Simeprevir Simeprevir is a competitive, reversible, macrocyclic, noncovalent hepatitis C virus (HCV) NS3/4A protease inhibitor that acts directly against the hepatitis C virus. It has a medium inhibitory concentration (IC50) <13 nM for all HCV NS3/4A enzymes(genotypes 1a, 1b, 2, 4, 5, and 6), but has an IC50 value of 37 nM for genotype 3.
Chemistry, 2022, e202202798.
Cell Rep, 2021, 35(7):109133
Viruses, 2021, 13(2)173
S4935 Asunaprevir Asunaprevir is an orally bioavailable inhibitor of the hepatitis C virus enzyme serine protease NS3 that is necessary for protein processing required for viral replication.
Int J Mol Sci, 2023, 10.3390/ijms242115535
Nature, 2022, 604(7904):146-151
Chemistry, 2022, e202202798.
S3728 Grazoprevir Grazoprevir anhydrous (MK5172) is a Hepatitis C Virus NS3/4A Protease inhibitor with IC50 values of 7pM, 4pM, and 62pM for HCV genotype 1a, 1B, and 4 respectively.
Cell Res, 2024, 34(1):31-46
Cell Rep, 2021, 35(7):109133
Front Oncol, 2021, 11:803278
S3724 Velpatasvir Velpatasvir (GS-5816,VEL) is a second-generation NS5A inhibitor that inhibits hepatitis C viral replication through acting on the crucial "membranous web" that facilitates RNA replication.
mBio, 2023, 10.1128/mbio.01318-23
Front Oncol, 2021, 11:803278
Front Microbiol, 2020, 10:2936
S5403 Ombitasvir (ABT-267) Ombitasvir (ABT-267) is an inhibitor of the HCV non-structural protein 5A with antiviral activity.
Commun Biol, 2022, 5(1):154
Sci Rep, 2021, 11(1):19443
bioRxiv, 2021, 2021.07.21.453274
S5402 Dasabuvir (ABT-333) Dasabuvir (ABT-333) is a non-nucleoside inhibitor of NS5B viral RNA-dependent RNA polymerase that inhibits recombinant NS5B polymerases derived from HCV genotype 1a and 1b clinical isolates with IC50 values between 2.2 and 10.7 nM. It is at least 7,000-fold selective for the inhibition of HCV genotype 1 polymerases over human/mammalian polymerases.
J Virus Erad, 2022, 8(2):100074
mSphere, 2021, 6(6):e0062321
Sci Rep, 2021, 11(1):19443
S5720 Glecaprevir Glecaprevir(ABT-493) is a hepatitis C virus (HCV) nonstructural (NS) protein 3/4A protease inhibitor that targets the the viral RNA replication. It displays IC50 values ranging from 3.5 to 11.3 nM for clinical isolates of HCV genotypes 1a, 1b, 2a, 2b, 3a, 4a, 5a, and 6a.
Cell Rep, 2021, 35(7):109133
Sci Rep, 2021, 11(1):19443
BioRxiv, 2020, 10.1101/2020.12.13.422511
S5404 Paritaprevir (ABT-450) Paritaprevir (ABT-450) is a nonstructural (NS) protein 3/4A protease inhibitor.
Cell Rep, 2021, 35(7):109133
BioRxiv, 2020, 10.1101/2020.12.13.422511
S3800 Lycorine hydrochloride Lycorine (Galanthidine, Amarylline, Narcissine, Licorine), a natural alkaloid extracted from the Amaryllidaceae plant family, has been reported to exhibit a wide range of physiological effects, including the potential effect against cancer. It is an HCV inhibitor with strong activity.
Aging Cell, 2021, e13307
S5307 PSI-6206 (GS-331007) PSI-6206 (RO-2433, GS-331007) is a potent inhibitor of the hepatitis C virus RNA-dependent RNA polymerase, targeting NS5B polymerase.
J Virus Erad, 2022, 8(2):100074
S3395 Tegobuvir Tegobuvir (TGV, GS 333126, GS-9190) is a non-nucleoside inhibitor of HCV RNA replication with proven antiviral activity in HCV-infected patients.
S9641 Pibrentasvir (ABT-530) Pibrentasvir (ABT-530) is a novel and pan-genotypic hepatitis C virus (HCV) NS5A inhibitor with EC50 ranging from 1.4 pM to 5.0 pM against HCV replicons containing NS5A from genotypes 1 to 6.
S5394 Tizoxanide Tizoxanide (Desacetyl-nitazoxanide), a thiazolide anti-infective, is active against anaerobic bacteria, protozoa, and a range of viruses in cell culture models, and is currently in phase II clinical development for treating chronic hepatitis C.
Mol Ther, 2024, S1525-0016(24)00340-X
Int J Mol Sci, 2024, 25(8)4413
E0097 Mericitabine Mericitabine (RG 7128, R-7128, PSI 6130 diisobutyrate) is a nucleoside inhibitor of the HCV NS5B polymerase that acts as an RNA chain terminator and prevents elongation of RNA transcripts during replication.
S5652 Elbasvir Elbasvir (MK8742) is an NS5A inhibitor, preventing hepatitis C viral RNA replication and virion assembly. Median EC50 values range from 0.2 to 3600 pmol/L, based on genotype.
E3597 Herba taxilli Extract Herba Taxilli Extract is extracted from Taxillus sutchuenensis, which can be used as inhibitors of HCV NS3 serine protease.
S2074 Mecarbinate Mecarbinate (Dimecarbin) is a chemical intermediate of arbidol hydrochloride.
E1243 Azvudine Azvudine (RO-0622) is a novel nucleoside reverse transcriptase inhibitor with antiviral activity against human immunodeficiency virus (HIV), hepatitis B virus (HBV) and hepatitis C virus (HCV), potently inhibits HIV-1 (EC50 range 0.03 to 6.92 nM) and HIV-2 (EC50s ranging from 0.018 to 0.025 nM).
S1482 Daclatasvir (BMS-790052) Daclatasvir (BMS-790052, EBP883) is a highly selective inhibitor of HCV NS5A with EC50 of 9-50 pM, for a broad range of HCV replicon genotypes and the JFH-1 genotype 2a infectious virus in cell culture. Phase 3.
J Med Virol, 2024, 96(7):e29787
EMBO Mol Med, 2024, 16(4):870-884
J Virol, 2024, e0192123.
S1538 Telaprevir Telaprevir is an HCV NS3-4A serine protease inhibitor with IC50 of 0.35 μM.
J Virol, 2024, e0192123.
bioRxiv, 2023, 2023.11.22.568224
NPJ Digit Med, 2022, 5(1):83
S2794 Sofosbuvir Sofosbuvir is a HCV NS5B polymerase inhibitor for the treatment of chronic hepatitis C virus (HCV) infection.
J Med Virol, 2024, 96(7):e29787
PLoS One, 2024, 19(5):e0303265
mBio, 2023, 10.1128/mbio.01318-23
S1480 Lomibuvir (VX-222) Lomibuvir (VX-222, VCH-222) is a novel, potent and selective inhibitor of HCV polymerase with IC50 of 0.94-1.2 μM, 15.3-fold less effective for mutant M423T, and 108-fold less effective for mutant I482L. Phase 2.
Cell Death Discov, 2022, 8(1:446)
J Virol, 2022, jvi0190621
Sci Rep, 2021, 11(1):19443
S1183 Danoprevir Danoprevir is a peptidomimetic inhibitor of the NS3/4A protease of hepatitis C virus (HCV) with IC50 of 0.2-3.5 nM, inhibition effect for HCV genotypes 1A/1B/4/5/6 is ~10-fold higher than 2B/3A. Phase 2.
Antimicrob Agents Chemother, 2024, 68(4):e0137323.
Viruses, 2023, 15(4)981
Cell Rep Methods, 2023, 3(10):100599
S3733 Boceprevir Boceprevir (EBP 520, SCH 503034) is an oral, direct acting hepatitis C virus (HCV) protease inhibitor with Ki value of 14 nM for NS3. It is used in combination with other antiviral agents in the treatment of chronic hepatitis C, genotype 1.
Eur J Med Chem, 2024, 268:116202
Int J Mol Sci, 2024, 25(11)5767
SLAS Discov, 2024, S2472-5552(24)00043-1
S5062 Daclatasvir Dihydrochloride Daclatasvir is an orally available antiviral agent that inhibits the NS5A region of the hepatitis C virus (HCV) used for the treatment of chronic HCV genotype 1 and 3 infection.
Commun Biol, 2022, 5(1):154
J Antimicrob Chemother, 2021, 76(7):1874-1885
Med Mol Morphol, 2021, 10.1007/s00795-020-00271-5
S7579 Ledipasvir (GS5885) Ledipasvir (GS5885) is a HCV NS5A polymerase inhibitor, used for the treatment of hepatitis C virus infection.
Sci Rep, 2021, 11(1):19443
Cancers (Basel), 2019, 11(10)E1407
Biol Pharm Bull, 2019, 10.1248/bpb.b19-00641
S5015 Simeprevir Simeprevir is a competitive, reversible, macrocyclic, noncovalent hepatitis C virus (HCV) NS3/4A protease inhibitor that acts directly against the hepatitis C virus. It has a medium inhibitory concentration (IC50) <13 nM for all HCV NS3/4A enzymes(genotypes 1a, 1b, 2, 4, 5, and 6), but has an IC50 value of 37 nM for genotype 3.
Chemistry, 2022, e202202798.
Cell Rep, 2021, 35(7):109133
Viruses, 2021, 13(2)173
S4935 Asunaprevir Asunaprevir is an orally bioavailable inhibitor of the hepatitis C virus enzyme serine protease NS3 that is necessary for protein processing required for viral replication.
Int J Mol Sci, 2023, 10.3390/ijms242115535
Nature, 2022, 604(7904):146-151
Chemistry, 2022, e202202798.
S3728 Grazoprevir Grazoprevir anhydrous (MK5172) is a Hepatitis C Virus NS3/4A Protease inhibitor with IC50 values of 7pM, 4pM, and 62pM for HCV genotype 1a, 1B, and 4 respectively.
Cell Res, 2024, 34(1):31-46
Cell Rep, 2021, 35(7):109133
Front Oncol, 2021, 11:803278
S3724 Velpatasvir Velpatasvir (GS-5816,VEL) is a second-generation NS5A inhibitor that inhibits hepatitis C viral replication through acting on the crucial "membranous web" that facilitates RNA replication.
mBio, 2023, 10.1128/mbio.01318-23
Front Oncol, 2021, 11:803278
Front Microbiol, 2020, 10:2936
S5403 Ombitasvir (ABT-267) Ombitasvir (ABT-267) is an inhibitor of the HCV non-structural protein 5A with antiviral activity.
Commun Biol, 2022, 5(1):154
Sci Rep, 2021, 11(1):19443
bioRxiv, 2021, 2021.07.21.453274
S5402 Dasabuvir (ABT-333) Dasabuvir (ABT-333) is a non-nucleoside inhibitor of NS5B viral RNA-dependent RNA polymerase that inhibits recombinant NS5B polymerases derived from HCV genotype 1a and 1b clinical isolates with IC50 values between 2.2 and 10.7 nM. It is at least 7,000-fold selective for the inhibition of HCV genotype 1 polymerases over human/mammalian polymerases.
J Virus Erad, 2022, 8(2):100074
mSphere, 2021, 6(6):e0062321
Sci Rep, 2021, 11(1):19443
S5720 Glecaprevir Glecaprevir(ABT-493) is a hepatitis C virus (HCV) nonstructural (NS) protein 3/4A protease inhibitor that targets the the viral RNA replication. It displays IC50 values ranging from 3.5 to 11.3 nM for clinical isolates of HCV genotypes 1a, 1b, 2a, 2b, 3a, 4a, 5a, and 6a.
Cell Rep, 2021, 35(7):109133
Sci Rep, 2021, 11(1):19443
BioRxiv, 2020, 10.1101/2020.12.13.422511
S5404 Paritaprevir (ABT-450) Paritaprevir (ABT-450) is a nonstructural (NS) protein 3/4A protease inhibitor.
Cell Rep, 2021, 35(7):109133
BioRxiv, 2020, 10.1101/2020.12.13.422511
S3800 Lycorine hydrochloride Lycorine (Galanthidine, Amarylline, Narcissine, Licorine), a natural alkaloid extracted from the Amaryllidaceae plant family, has been reported to exhibit a wide range of physiological effects, including the potential effect against cancer. It is an HCV inhibitor with strong activity.
Aging Cell, 2021, e13307
S5307 PSI-6206 (GS-331007) PSI-6206 (RO-2433, GS-331007) is a potent inhibitor of the hepatitis C virus RNA-dependent RNA polymerase, targeting NS5B polymerase.
J Virus Erad, 2022, 8(2):100074
S3395 Tegobuvir Tegobuvir (TGV, GS 333126, GS-9190) is a non-nucleoside inhibitor of HCV RNA replication with proven antiviral activity in HCV-infected patients.
S9641 Pibrentasvir (ABT-530) Pibrentasvir (ABT-530) is a novel and pan-genotypic hepatitis C virus (HCV) NS5A inhibitor with EC50 ranging from 1.4 pM to 5.0 pM against HCV replicons containing NS5A from genotypes 1 to 6.
S5394 Tizoxanide Tizoxanide (Desacetyl-nitazoxanide), a thiazolide anti-infective, is active against anaerobic bacteria, protozoa, and a range of viruses in cell culture models, and is currently in phase II clinical development for treating chronic hepatitis C.
Mol Ther, 2024, S1525-0016(24)00340-X
Int J Mol Sci, 2024, 25(8)4413
E0097 Mericitabine Mericitabine (RG 7128, R-7128, PSI 6130 diisobutyrate) is a nucleoside inhibitor of the HCV NS5B polymerase that acts as an RNA chain terminator and prevents elongation of RNA transcripts during replication.
S5652 Elbasvir Elbasvir (MK8742) is an NS5A inhibitor, preventing hepatitis C viral RNA replication and virion assembly. Median EC50 values range from 0.2 to 3600 pmol/L, based on genotype.
E3597 Herba taxilli Extract Herba Taxilli Extract is extracted from Taxillus sutchuenensis, which can be used as inhibitors of HCV NS3 serine protease.
S2074 Mecarbinate Mecarbinate (Dimecarbin) is a chemical intermediate of arbidol hydrochloride.
E1243 Azvudine Azvudine (RO-0622) is a novel nucleoside reverse transcriptase inhibitor with antiviral activity against human immunodeficiency virus (HIV), hepatitis B virus (HBV) and hepatitis C virus (HCV), potently inhibits HIV-1 (EC50 range 0.03 to 6.92 nM) and HIV-2 (EC50s ranging from 0.018 to 0.025 nM).

Choose Selective HCV Protease Inhibitors

HCV ProteaseSignaling Pathway

HCV Protease信号通路图
Tags: HCV protease treatment | HCV protease assay | HCV protease inhibitors review